Table S1. Characterization of included studies.

First author	Ref.	Pt	country	Enterococci No.	species	Samples	Method of antimicrobial susceptibility testing	Guidelines used to interpret antimicrobial sensitivities	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Total score
HSUEH	(1)	2001	Taiwan	125	Enterococcus spp.	Blood & other samples	DDM	NCCLS	1	1	1	1	1	1	1	0	0	7
Wroblewska	(2)	2002	Poland	3	E. faecalis	Blood	DDM	NCCLS	1	1	0	1	1	0	1	0	1	6
Rodriguez	(3)	2002	USA	162	E. faecalis	Blood & other samples	DDM	NCCLS	1	1	1	1	1	1	1	0	0	7
Hernandez	(4)	2002	Spain	377	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Wroblewska	(2)	2002	Poland	5	E. faecium	Blood	DDM	NCCLS	1	1	0	1	1	0	1	0	1	6
Rodriguez	(3)	2002	USA	16	E. faecium	ND*****	DDM	NCCLS	1	1	1	1	1	1	1	0	0	7
Hernandez	(4)	2002	Spain	52	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Woodford	(5)	2003	UK and Ireland	152	E. faecalis	Blood	UN	UN	1	1	1	0	1	1	1	0	1	7
Arias	(6)	2003	Colombia	101	E. faecalis	Blood & other samples	MIC	NCCLS	1	1	1	1	1	1	1	0	1	8
Johnson	(7)	2003	UK	166	E. faecalis	Blood & other samples	MIC	BSAC	1	1	1	1	1	1	1	0	0	7
Mathur	(8)	2003	India	444	E. faecalis	Blood & other samples	MIC	NCCLS	0	0	1	0	0	0	0	0	0	1
feizabadi	(9)	2003	Iran	59	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	0	1	1	1	0	0	5
Arias	(6)	2003	Colombia	18	E. faecium	Blood & other samples	MIC	NCCLS	1	1	1	1	1	1	1	0	1	8
Johnson	(7)	2003	UK	56	E. faecium	Blood & other samples	MIC	BSAC	1	1	1	1	1	1	1	0	0	7
feizabadi	(9)	2004	Iran	273	E. faecalis	Blood & other samples	DDM	UN	1	0	1	0	1	1	1	0	0	5
Karmarkar	(10)	2004	India	10	E. faecalis	Blood & other samples	DDM	NCCLS	1	0	0	0	0	0	0	0	0	1
feizabadi	(9)	2004	Iran	66	E. faecium	Blood & other samples	DDM	UN	1	0	1	0	1	1	1	0	0	5
Karmarkar	(10)	2004	India	42	E. faecium	Blood & other samples	DDM	NCCLS	1	0	0	0	0	0	0	0	0	1
BLAHOVÁ	(11)	2004	Slovak Republic	32	Enterococcus spp.	Blood	DDM	NCCLS	0	0	0	0	1	0	1	0	0	2
Streit	(12)	2004	North America	95	Enterococcus spp.	Blood & other samples	MIC	NCCLS	1	1	1	1	1	1	1	0	1	8
feizabadi	(9)	2004	Tehran	342	Enterococcus spp.	Blood & other samples	DDM	UN	1	0	1	0	0	1	1	0	0	4
Kapoor	(13)	2005	India	10	E. faecalis	Blood	DDM		1	1	1	1	1	1	1	0	0	7
Stampone	(14)	2005	Italy	918	E. faecalis	Blood	MIC	NCCLS	1	1	1	1	1	1	1	0	1	8

Quinones	(15)	2005	Cuba	84	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Kacmaz	(16)	2005	Turkey	207	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	1	8
Kapoor	(13)	2005	India	33	E. faecium	Blood	DDM	UN	1	1	1	1	1	1	1	0	0	7
Stampone	(14)	2005	Italy	345	E. faecium	Blood	MIC	NCCLS	1	1	1	1	1	1	1	0	1	8
Quinones	(15)	2005	Cuba	10	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Kacmaz	(16)	2005	Turkey	25	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2005	(a)	1245	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
SHAKED	(18)	2006	Israel	93	E. faecalis	Blood & other samples	UN	NCCLS	1	1	1	1	1	1	1	1	0	8
KLIBI	(19)	2006	Tunis	139	E. faecalis	Blood & other samples	DDM	CASFM	1	1	1	1	1	1	1	0	0	7
Waites	(20)	2006	USA	740	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Ghoshal	(21)	2006	India	456	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
SHAKED	(18)	2006	Israel	22	E. faecium	Blood	UN	NCCLS	1	1	1	1	1	1	1	1	0	8
KLIBI	(19)	2006	Tunis	41	E. faecium	Blood & other samples	DDM	CASFM	1	1	1	1	1	1	1	0	0	7
Waites	(20)	2006	USA	280	E. faecium	ND	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Ghoshal	(21)	2006	India	229	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Sader	(17)	2006	Belgium	48	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	France	247	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Germany	353	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Greece	62	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Ireland	80	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Israel	39	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Italy	166	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Poland	32	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Russia	23	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Spain	114	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Sweden	131	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	Switzerland	58	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6

Sader	(17)	2006	Turkey	134	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2006	UK	99	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
WangXD		2006	China	112	Enterococcus spp.		UN	UN	1	1	1	0	1	0	1	0	0	5
Sader	(17)	2007	France	104	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Germany	117	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Greece	7	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Ireland	38	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Israel	34	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Italy	61	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Poland	40	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Spain	39	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Sweden	96	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Switzerland	21	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Turkey	61	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	UK	28	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Młynarczyk	(22)	2007	Poland	42	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	61	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	59	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	68	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	73	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Sader	(17)	2007	France	18	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Germany	73	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Greece	6	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Ireland	14	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Israel	10	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Italy	36	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8

Sader	(17)	2007	Poland	23	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Spain	14	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Sweden	21	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Switzerland	4	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Sader	(17)	2007	Turkey	70	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Młynarczyk	(22)	2007	Poland	64	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	73	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	77	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	84	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Młynarczyk	(22)	2007	Poland	162	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Sader	(17)	2007	UK	18	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Mendiratta	(23)	2008	India	128	E. faecalis	Blood & other samples	MIC	NCCLS	1	0	1	0	1	1	1	0	0	5
Emaneini	(24)	2008	Iran	210	E. faecalis	Blood & other samples	DDM	NCCLS	1	1	1	1	1	1	1	0	0	7
Agarwal	(25)	2008	India	42	E. faecalis	Blood & other samples	DDM	NCCLS	1	1	1	1	1	0	1	0	0	6
Billström	(26)	2008	Sweden	263	E. faecium	Blood	MIC		1	0	1	1	1	1	1	1	0	7
Mendiratta	(23)	2008	India	22	E. faecium	Blood & other samples	DDM	NCCLS	1	0	1	0	1	1	1	0	0	5
Emaneini	(24)	2008	Iran	116	E. faecium	Blood & other samples	DDM	NCCLS	1	1	1	1	1	1	1	0	0	7
Agarwal	(25)	2008	India	33	E. faecium	Blood & other samples	DDM	NCCLS	1	1	1	1	1	0	1	0	0	6
Zhanel	(27)	2008	Canada	74	Enterococcus spp.	Blood	DDM	CLSI	1	1	1	1	1	1	1	1	1	9
Jarousha	(28)	2008	Palestine	6	Enterococcus spp.	Blood & other samples	DDM	UN	1	0	0	0	0	0	0	0	0	1
CLAESSON	(29)	2009	Sweden	429	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	1	0	8
Montravers	(30)	2009	France	59	E. faecalis	Blood & other samples	UN	CASFM	1	1	1	1	1	1	1	1	1	9
Sader	(17)	2009	Argentina	244	E. faecalis	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2009	Brazil	836	E. faecalis	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2009	Chile	276	E. faecalis	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
Sader	(17)	2009	Mexico	325	E. faecalis	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6

Gales	(31)	2009	Brazil	625	E. faecalis	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
YASLIANI	(32)	2009	Iran	160	E. faecalis	Blood & other samples	DDM	UN	1	1	1	0	0	1	1	0	0	5
CLAESSON	(29)	2009	Sweden	241	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	1	0	8
Montravers	(30)	2009	France	24	E. faecium	Blood & other samples	UN	CASFM	1	1	1	1	1	1	1	1	1	9
Sader	(17)	2009	Argentina	52	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Sader	(17)	2009	Brazil	146	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Sader	(17)	2009	Chile	54	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Sader	(17)	2009	Mexico	130	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
Gales	(31)	2009	Brazil	102	E. faecium	Blood & other samples	MIC	CLSI	1	1	0	1	1	1	1	0	0	6
YASLIANI	(32)	2009	Iran	22	E. faecium	Blood & other samples	DDM	UN	1	1	1	0	0	1	1	0	0	5
Adhikari	(33)	2010	India	130	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Protonotariou	(34)	2010	Greece	145	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	232	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	256	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	230	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	293	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	342	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Adhikari	(33)	2010	India	17	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Protonotariou	(34)	2010	Greece	47	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	85	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	111	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	89	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	142	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Protonotariou	(34)	2010	Greece	151	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
KOHLI	(35)	2010	NAIROBI	43	Enterococcus spp.	Blood	DDM	CLSI	1	1	0	1	0	0	1	0	0	4
Adhikari	(33)	2010	India	180	Enterococcus spp.	Blood & other samples	UN	UN	1	0	1	1	0	1	1	0	0	5

Araoka	(36)	2011	Japan	62	E. faecalis	Blood	MIC	UN	1	1	1	1	1	1	1	0	0	7
Jain	(37)	2011	Delhi	36	E. faecalis	Blood & other samples	DDM	CLSI	1	1	1	1	1	1	1	0	0	7
Zhanel	(27)	2011	Canada	393	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Jain	(37)	2011	Delhi	58	E. faecium	Blood	DDM	CLSI	1	1	1	1	1	1	1	0	0	7
Araoka	(36)	2011	Japan	71	E. faecium	Blood	MIC		1	1	1	1	1	1	1	0	0	7
Zhanel	(38)	2011	Canada	152	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Mira	(39)	2011	Serbia	89	Enterococcus spp.	Blood	DDM	CLSI	1	1	0	1	1	1	1	0	0	6
Aslan	(40)	2011	Turkey	15	Enterococcus spp.	Blood	DDM	CLSI	1	1	0	0	1	1	1	0	1	6
Olawale	(41)	2011	Nigeria	7	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	0	0	0	0	0	0	0	2
Conceição	(42)	2011	Brazil	80	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
Conceição	(42)	2011	Brazil	72	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
Conceição	(42)	2011	Brazil	69	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
Conceição	(42)	2011	Brazil	103	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
ARSE	(43)	2012	Austria	425	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Belgium	393	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Bulgaria	78	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Croatia	160	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Cyprus	77	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Czech Republic	251	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Denmark	112	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
Hammerum	(44)	2012	Denmark	164	E. faecalis	Blood	UN	EUCAST	1	1	1	1	1	1	1	0	0	7
El-Din	(45)	2012	Egypt	70	E. faecalis	Blood	DDM	CLSI	1	1	1	1	1	0	1	0	0	6
ARSE	(43)	2012	Estonia	19	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Finland	274	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	France	1,528	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Germany	680	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Greece	667	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Hungary	452	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Iceland	20	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Ireland	279	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Italy	300	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Latvia	55	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9

ARSE	(43)	2012	Lithuania	59	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Luxembourg	45	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Malta	6	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Netherlands	287	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Norway	123	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Poland	105	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Portugal	347	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Slovakia	179	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Slovenia	129	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Spain	878	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Sweden	792	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	United Kingdom	377	E. faecalis	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
Kuch	(46)	2012	Denmark	40	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Kuch	(46)	2012	Norway	30	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Kuch	(46)	2012	Poland	75	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Kuch	(46)	2012	Spain	41	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Kuch	(46)	2012	The Netherlands	59	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Bekhit	(47)	2012	Saudi Arabia	166	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	0	1	7
Nepal	(48)	2012	Nepal	73	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	0	0	0	1	0	0	3
DJAHMI	(49)	2012	Algeria	80	E. faecalis	Blood & other samples	DDM	CASFM	1	1	1	0	1	1	1	0	0	6
Sreeja	(50)	2012	India	97	E. faecalis	Blood & other samples	DDM	CLSI	1	1	1	1	0	1	1	0	0	6
ARSE	(43)	2012	Austria	376	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Belgium	212	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Bulgaria	42	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Croatia	61	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Cyprus	29	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Czech Republic	262	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Denmark	593	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
Hammerum	(44)	2012	Denmark	101	E. faecium	Blood	UN	EUCAST	1	1	1	1	1	1	1	0	0	7
AlmEl-Din	(45)	2012	Egypt	35	E. faecium	Blood	DDM	CLSI	1	1	1	1	1	0	1	0	0	6
ARSE	(43)	2012	Estonia	40	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Finland	274	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9

ARSE	(43)	2012	France	614	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Germany	647	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Greece	418	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Hungary	142	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Iceland	14	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Ireland	386	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Italy	435	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Latvia	18	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Lithuania	36	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Luxembourg	20	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Netherlands	484	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Norway	168	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Poland	157	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Portugal	257	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Slovakia	82	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Slovenia	95	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Spain	537	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	Sweden	404	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
ARSE	(43)	2012	UK	362	E. faecium	Blood	UN	UN	1	1	1	1	1	1	1	1	1	9
Bekhit	(47)	2012	Saudi Arabia	27	E. faecium	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	0	1	7
Nepal	(48)	2012	Nepal	25	E. faecium	Blood & other samples	DDM	CLSI	1	0	1	0	0	0	1	0	0	3
DJAHMI	(49)	2012	Algeria	39	E. faecium	Blood & other samples	DDM	CASFM	1	1	1	0	1	1	1	0	0	6
Sreeja	(50)	2012	India	31	E. faecium	Blood & other samples	DDM	CLSI	1	1	1	1	0	1	1	0	0	6
Soltani	(51)	2012	Iran	30	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	1	1	0	1	0	0	6
Khalili	(52)	2012	Iran	60	Enterococcus spp.	Blood & other samples	DDM	UN	1	1	1	0	1	0	1	0	0	5
Khalili	(52)	2012	Iran	60	Enterococcus spp.	Blood & other samples	DDM	UN	1	1	1	0	1	0	1	0	0	5
Khalili	(52)	2012	Iran	60	Enterococcus spp.	Blood & other samples	DDM	UN	1	1	1	0	1	0	1	0	0	5
Khalili	(52)	2012	Iran	60	Enterococcus spp.	Blood & other samples	DDM	UN	1	1	1	0	1	0	1	0	0	5
Sharifi	(53)	2012	Iran	220	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
Coombs	(54)	2013	Australia	658	E. faecalis	Blood	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
TayWang	(55)	2013	Taiwan	333	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	352	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8

TayWang	(55)	2013	Taiwan	335	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	317	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	359	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Fernandes	(56)	2013	India	84	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Coombs	(54)	2013	Australia	375	E. faecium	Blood	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
TayWang	(55)	2013	Taiwan	49	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	66	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	75	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	115	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
TayWang	(55)	2013	Taiwan	147	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	0	8
Fernandes	(56)	2013	India	51	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	1	1	0	0	7
Praharaj	(57)	2013	India	367	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	1	1	1	1	0	0	7
CELIK	(58)	2014	Turkey	63	E. faecalis	Blood & other samples	DDM	UN	1	1	1	1	1	0	1	0	0	6
Samadi	(59)	2014	Iran	106	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	1	1	0	1	0	0	5
Padmasini	(60)	2014	India	86	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
CELIK	(58)	2014	Turkey	59	E. faecium	Blood & other samples	DDM	UN	1	1	1	1	1	0	1	0	0	6
Moemen	(61)	2014	Egypt	52	E. faecium	Blood & other samples	DDM	CLSI	1	1	1	1	1	1	1	1	0	8
Samadi	(59)	2014	Iran	80	E. faecium	Blood & other samples	DDM	CLSI	1	0	1	1	1	0	1	0	0	5
Padmasini	(60)	2014	India	80	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	0	7
singh		2014	India	201	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	1	0	1	0	0	5
Sirkhazi	(62)	2014	Saudi Arabia	8	Enterococcus spp.	Blood & other samples	UN	CLSI	0	0	0	0	1	0	1	0	0	2
Babar	(63)	2014	Pakistan	190	Enterococcus spp.	Blood & other samples	DDM	UN	1	1	1	0	1	0	1	0	0	5
Abat	(64)	2015	France	156	E. faecalis	Blood	DDM	EUCAST	1	1	1	1	1	1	1	1	0	8
Kajihara	(65)	2015	Japan	144	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Bhatt	(66)	2015	India	150	E. faecalis	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
NASAJ	(67)	2015	Iran	175	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	0	0	6

Abat	(64)	2015	France	51	E. faecium	Blood	DDM	EUCAST	1	1	1	1	1	1	1	1	0	8
Kajihara	(65)	2015	Japan	38	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	1	1	9
Bhatt	(66)	2015	India	50	E. faecium	Blood & other samples	DDM	CLSI	1	1	1	0	1	1	1	0	0	6
NASAJ	(67)	2015	Iran	67	E. faecium	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	0	0	6
Chakraborty	(68)	2015	India	153	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	0	0	1	1	0	0	5
HoseiniZadeh	(69)	2015	Iran	200	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	1	0	1	1	0	0	6
Maina	(70)	2016	Kenya	28	E. faecalis	Blood	DDM	CLSI	1	1	1	1	1	1	1	1	0	8
Gawryszewska	(71)	2016	Poland	140	E. faecalis	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Arabestani	(72)	2016	Iran	175	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	1	0	7
Tuhina	(73)	2016	India	21	E. faecalis	Blood & other samples	DDM	CLSI	1	1	1	1	1	1	1	0	0	7
Gawryszewska	(71)	2016	Poland	112	E. faecium	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Arabestani	(72)	2016	Iran	67	E. faecium	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	1	0	7
Flamm	(74)	2016	USA	855	Enterococcus spp.	Blood & other samples	MIC	CLSI	1	1	1	1	1	1	1	0	1	8
Paul Biswas	(75)	2016	India	500	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	0	1	0	1	1	1	0	0	5
Mittal	(76)	2016	India	100	Enterococcus spp.	Blood & other samples	DDM	CLSI	0	0	1	0	1	1	1	0	0	4
Phukan	(77)	2016	India	67	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	0	1	1	1	1	1	0	0	6
Armin	(78)	2017	Iran	9	E. faecalis	Blood	DDM	CLSI	1	1	0	1	1	1	1	0	0	6
Jaramago	(79)	2017	spain	15	E. faecalis	Blood & other samples	DDM	CLSI	1	0	1	1	1	0	1	0	0	5
Jahansepas	(80)	2017	Iran	125	E. faecalis	Blood & other samples	DDM	CLSI	1	1	1	1	1	1	1	0	1	8
Jaramago	(79)	2017	Spain	11	E. faecium	Blood	DDM	CLSI	1	0	1	1	1	0	1	0	0	5
Jahansepas	(80)	2017	Iran	35	E. faecium	Blood & other samples	DDM	CLSI	1	1	1	1	1	1	1	0	1	8
Yilema	(81)	2017	Ethiopia	24	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	1	1	0	1	1	1	8
Yilema	(81)	2017	Ethiopia	24	Enterococcus spp.	Blood & other samples	DDM	CLIS	1	1	1	1	1	0	1	1	1	8
Pitiriga	(82)	2018	Greece	55	E. faecalis	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	108	E. faecalis	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	67	E. faecalis	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	57	E. faecalis	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8

Pitiriga	(82)	2018	Greece	55	E. faecalis	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	108	E. faecalis	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	67	E. faecalis	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	57	E. faecalis	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	15	E. faecium	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	28	E. faecium	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	11	E. faecium	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	5	E. faecium	Blood & other samples	UN	CLSI	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	15	E. faecium	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	28	E. faecium	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	11	E. faecium	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Pitiriga	(82)	2018	Greece	5	E. faecium	Blood & other samples	UN	UN	1	1	1	1	1	1	1	1	0	8
Karimzadeh	(83)	2018	Iran	89	Enterococcus spp.	Blood & other samples	DDM	CLSI	1	1	1	1	1	0	1	0	0	6

MIC: Minimum Inhibitory Concentration, DDM: Disc diffusion method, NCCLS: National Committee for Clinical Laboratory Standards, CLSI: The Clinical & Laboratory Standards Institute, BSAC: British Society for Antimicrobial Chemotherapy, EUCAST: European Committee on Antimicrobial Susceptibility Testing, ARSE: Antimicrobial resistance surveillance in Europe ; (a)North America, South America, Europe, and the Asia–Australia areas, UN: Non Known ; Q1: Was the sample frame appropriate to address the target population? ; Q2: Were study participants sampled in an appropriate way? ; Q3: Was the sample size adequate? ; Q4: Were the study subjects and the setting described in detail? ; Q5: Was the data analysis conducted with sufficient coverage of the identified sample? ; Q6: Were valid methods used for the identification of the condition? ; Q7: Was the condition measured in a standard, reliable way for all participants? ; Q8: Was there appropriate statistical analysis? ; Q9: Was the response rate adequate, and if not, was the low response rate managed appropriately?; 0: NO; 1: YES.

Table S2. Prevalence of Vancomycin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	88	0.019	0.014	0.025	-26.812	0.000	390.420	87	0.000	77.716
E. faecium	108	0.101	0.079	0.128	-15.820	0.000	1728.756	107	0.000	93.811
Enterococcus	49	0.119	0.094	0.149	-14.922	0.000	435.481	48	0.000	88.978
Total between							2554.657	242	0.000	
Overall	245	0.066	0.057	0.077	-32.841	0.000	799.228	2	0.000	
							3353.885	244	0.000	92.725

Table S3 Prevalence of Gentamicin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	89	0.364	0.331	0.398	-7.621	0.000	1750.396	88	0.000	94.973
E. faecium	53	0.465	0.391	0.541	-0.890	0.374	853.882	52	0.000	93.910
Enterococcus	39	0.356	0.306	0.410	-5.088	0.000	489.642	38	0.000	92.239
Total between							3093.920	178	0.000	
Overall	181	0.375	0.349	0.402	-8.838	0.000	262.275	2	0.000	
							3356.195	180	0.000	94.637

Table S4 Prevalence of Ampicillin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	48	0.040	0.023	0.068	-11.049	0.000	1417.382	47	0.000	96.684
E. faecium	45	0.781	0.732	0.824	9.277	0.000	373.940	44	0.000	88.233
Enterococcus	40	0.264	0.218	0.315	-7.990	0.000	495.883	39	0.000	92.135
Total between							2287.205	130	0.000	
Overall	133	0.435	0.393	0.478	-2.932	0.003	1928.046	2	0.000	
							4215.251	132	0.000	96.869

Table S5. Prevalence of Teicoplanin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	41	0.019	0.012	0.029	-17.887	0.000	221.278	40	0.000	81.923
E. faecium	36	0.146	0.093	0.221	-6.832	0.000	497.302	35	0.000	92.962
Enterococcus	33	0.077	0.057	0.104	-14.860	0.000	251.749	32	0.000	87.289
Total between							970.330	107	0.000	
Overall	110	0.060	0.048	0.074	-23.262	0.000	405.455	2	0.000	
							1375.785	109	0.000	92.077

Table S6. Prevalence of Linezolid resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	34	0.006	0.003	0.011	-16.556	0.000	133.054	33	0.000	75.198
E. faecium	34	0.017	0.010	0.028	-15.431	0.000	77.265	33	0.000	57.290
Enterococcus	32	0.007	0.005	0.012	-19.724	0.000	46.487	31	0.037	33.315
Total between							256.806	97	0.000	
Overall	100	0.009	0.007	0.013	-29.894	0.000	21.045	2	0.000	
							277.851	99	0.000	64.369

Table S7. Prevalence of Ciprofloxacin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	40	0.435	0.362	0.511	-1.683	0.092	1137.464	39	0.000	96.571
E. faecium	32	0.749	0.691	0.799	7.429	0.000	224.185	31	0.000	86.172
Enterococcus	27	0.494	0.418	0.570	-0.146	0.884	365.332	26	0.000	92.883
Total between							1726.981	96	0.000	
Overall	99	0.575	0.532	0.617	3.427	0.001	516.305	2	0.000	
							2243.286	98	0.000	95.631

Table S8. Prevalence of Streptomycin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	42	0.350	0.306	0.397	-6.015	0.000	637.802	41	0.000	93.572
E. faecium	35	0.507	0.422	0.592	0.161	0.872	442.158	34	0.000	92.310
Enterococcus	11	0.349	0.255	0.456	-2.731	0.006	208.117	10	0.000	95.195
Overall	88	0.384	0.346	0.423	-5.744	0.000	1523.631	87	0.000	94.290

Table S9. Prevalence of Erythromycin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	27	0.698	0.651	0.742	7.605	0.000	315.449	26	0.000	91.758
E. faecium	26	0.839	0.790	0.878	9.988	0.000	146.951	25	0.000	82.988
Enterococcus	16	0.611	0.469	0.737	1.535	0.125	399.763	15	0.000	96.248
Total between							862.162	66	0.000	
Overall	69	0.737	0.703	0.769	11.794	0.000	166.676	2	0.000	
							1028.838	68	0.000	93.391

Table S10. Prevalence of Penicillin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	26	0.180	0.119	0.264	-6.052	0.000	558.925	25	0.000	95.527
E. faecium	24	0.854	0.812	0.888	11.315	0.000	100.743	23	0.000	77.170
Enterococcus	16	0.355	0.265	0.455	-2.798	0.005	122.877	15	0.000	87.793
Total between							782.546	63	0.000	
Overall	66	0.610	0.556	0.661	3.963	0.000	1174.752	2	0.000	
							1957.298	65	0.000	96.679

Table S11. Prevalence of Chloramphenicol resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	19	0.302	0.233	0.382	-4.632	0.000	173.227	18	0.000	89.609
E. faecium	14	0.174	0.113	0.259	-6.028	0.000	60.274	13	0.000	78.432
Enterococcus	29	0.263	0.214	0.319	-7.428	0.000	216.421	28	0.000	87.062
Total between							449.922	59	0.000	
Overall	62	0.259	0.223	0.299	-10.377	0.000	30.980	2	0.000	
							480.902	61	0.000	87.316

Table S12. Prevalence of levofloxacin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	17	0.274	0.218	0.339	-6.275	0.000	329.940	16	0.000	95.151
E. faecium	17	0.793	0.726	0.847	7.159	0.000	83.510	16	0.000	80.841
Enterococcus	20	0.391	0.325	0.461	-3.019	0.003	263.377	19	0.000	92.786
Total between							676.827	51	0.000	
Overall	54	0.451	0.407	0.496	-2.124	0.034	830.706	2	0.000	
							1507.533	53	0.000	96.484

Table S13. Prevalence of Quinupristin/dalfopristin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	9	0.969	0.889	0.992	4.910	0.000	102.477	8	0.000	92.193
E. faecium	23	0.081	0.046	0.138	-7.964	0.000	265.986	22	0.000	91.729
Enterococcus	18	0.641	0.536	0.734	2.608	0.009	331.733	17	0.000	94.875
Total between							700.196	47	0.000	
Overall	50	0.444	0.362	0.530	-1.282	0.200	926.802	2	0.000	
							1626.997	49	0.000	96.988

Table S14. Prevalence of Tetracycline resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	21	0.815	0.746	0.869	7.135	0.000	378.480	20	0.000	94.716
E. faecium	16	0.590	0.492	0.681	1.810	0.070	136.573	15	0.000	89.017
Enterococcus	11	0.627	0.573	0.677	4.544	0.000	41.491	10	0.000	75.898
Total between							556.544	45	0.000	
Overall	48	0.661	0.620	0.699	7.443	0.000	236.529	2	0.000	
							793.073	47	0.000	94.074

Table S15. Prevalence of Daptomycin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	11	0.002	0.001	0.005	-14.473	0.000	5.320	10	0.869	0.000
E. faecium	12	0.006	0.002	0.012	-12.661	0.000	3.268	11	0.987	0.000
Enterococcus	17	0.005	0.003	0.009	-16.251	0.000	11.344	16	0.788	0.000
Total between							19.932	37	0.990	
Overall	40	0.004	0.003	0.006	-25.106	0.000	3.541	2	0.170	
							23.472	39	0.977	0.000

Table S16. Prevalence of Nitrofurantoin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	14	0.021	0.008	0.056	-7.436	0.000	119.399	13	0.000	89.112
E. faecium	14	0.431	0.305	0.567	-0.989	0.322	170.803	13	0.000	92.389
Enterococcus	5	0.160	0.094	0.261	-5.267	0.000	28.616	4	0.000	86.022
Total between							318.818	30	0.000	
Overall	33	0.214	0.157	0.285	-6.718	0.000	256.431	2	0.000	
							575.249	32	0.000	94.437

Table S17. Prevalence of Amoxicillin/clavuanic acid resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	5	0.032	0.005	0.185	-3.474	0.001	24.396	4	0.000	83.604
E. faecium	5	0.542	0.352	0.720	0.421	0.674	26.992	4	0.000	85.181
Enterococcus	9	0.178	0.089	0.323	-3.779	0.000	47.225	8	0.000	83.060
Total between							98.614	16	0.000	
Overall	19	0.294	0.196	0.415	-3.215	0.001	65.839	2	0.000	
							164.452	18	0.000	89.055

Table S18. Prevalence of Imipenem resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	6	0.049	0.006	0.312	-2.669	0.008	190.402	5	0.000	97.374
E. faecium	5	0.793	0.572	0.917	2.502	0.012	81.402	4	0.000	95.086
Enterococcus	5	0.020	0.002	0.144	-3.597	0.000	21.151	4	0.000	81.088
Total between							292.955	13	0.000	
Overall	16	0.448	0.255	0.659	-0.468	0.640	318.067	2	0.000	
							611.022	15	0.000	97.545

Table S19. Prevalence of Tigecycline resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	4	0.005	0.001	0.017	-8.372	0.000	1.632	3	0.652	0.000
E. faecium	4	0.011	0.002	0.046	-5.949	0.000	5.316	3	0.150	43.563
Enterococcus	3	0.001	0.000	0.006	-7.664	0.000	2.328	2	0.312	14.089
Total between							9.275	8	0.320	
Overall	11	0.005	0.002	0.010	-12.667	0.000	9.144	2	0.010	
							18.420	10	0.048	45.710

Table S20. Prevalence of Norfloxacin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	3	0.234	0.129	0.386	-3.212	0.001	18.045	2	0.000	88.917
E. faecium	3	0.703	0.402	0.893	1.341	0.180	13.369	2	0.001	85.040
Enterococcus	4	0.647	0.562	0.724	3.333	0.001	7.102	3	0.069	57.758
Total between							38.516	7	0.000	
Overall	10	0.573	0.496	0.647	1.851	0.064	120.811	2	0.000	
							159.327	9	0.000	94.351

Table S21. Prevalence of Amikacin resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	2	0.216	0.168	0.273	-8.147	0.000	0.002	1	0.965	0.000
E. faecium	2	0.309	0.206	0.435	-2.896	0.004	0.912	1	0.340	0.000
Enterococcus	6	0.174	0.064	0.392	-2.724	0.006	42.588	5	0.000	88.260
Total between							43.502	7	0.000	
Overall	10	0.233	0.190	0.283	-8.913	0.000	2.402	2	0.301	
							45.904	9	0.000	80.394

Table S22. Prevalence of linezolid resistance in blood isolated Enterococcus spp.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
E. faecalis	4	0.009	0.001	0.070	-4.387	0.000	7.891	3	0.048	61.980
E. faecium	3	0.009	0.002	0.043	-5.757	0.000	0.092	2	0.955	0.000
Enterococcus	2	0.012	0.002	0.058	-5.355	0.000	0.061	1	0.804	0.000
Total between							8.044	6	0.235	
Overall	9	0.010	0.004	0.027	-8.999	0.000	0.120	2	0.942	
							8.164	8	0.418	2.013

Table S23. Prevalence of vancomycin resistance in blood isolated *E. faecalis*. by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	2	0.010	0.001	0.070	-4.538	0.000	0.266	1	0.606	0.000
Americas	9	0.045	0.029	0.069	-13.139	0.000	43.793	8	0.000	81.732
Eastern	11	0.049	0.026	0.090	-9.027	0.000	44.731	10	0.000	77.644
Europe	48	0.011	0.008	0.016	-25.209	0.000	60.344	47	0.092	22.114
South-East	11	0.038	0.019	0.072	-9.270	0.000	26.627	10	0.003	62.444
Western	7	0.006	0.001	0.046	-4.887	0.000	99.515	6	0.000	93.971
Total between							275.276	82	0.000	
Overall	88	0.023	0.018	0.029	-31.374	0.000	115.144	5	0.000	
							390.420	87	0.000	77.716

Table S24. Prevalence of gentamycin resistance in blood isolated *E. faecalis*. by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	2	0.509	0.416	0.603	0.196	0.844	0.978	1	0.323	0.000
Americas	8	0.303	0.278	0.330	-13.318	0.000	12.753	7	0.078	45.109
Eastern	11	0.322	0.253	0.399	-4.354	0.000	82.945	10	0.000	87.944
Europe	49	0.358	0.312	0.408	-5.481	0.000	1159.817	48	0.000	95.861
South-East	12	0.427	0.310	0.552	-1.147	0.251	153.149	11	0.000	92.817
Western	7	0.437	0.337	0.542	-1.179	0.238	147.313	6	0.000	95.927
Total between							1556.954	83	0.000	
Overall	89	0.337	0.317	0.358	-14.224	0.000	193.443	5	0.000	
							1750.396	88	0.000	94.973

Table S25. Prevalence of ampicillin resistance in blood isolated *E. faecalis*. by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	**Number Studies**	**Point estimate**	**Lower limit**	**Upper limit**	**Z-value**	**P-value**	**Q-value**	**df (Q)**	**P-value**	**I-squared**
Mixed effects analysis										
Africa	2	0.010	0.001	0.070	-4.538	0.000	0.266	1	0.606	0.000
Americas	9	0.014	0.010	0.019	-27.482	0.000	7.844	8	0.449	0.000
Eastern	7	0.117	0.067	0.196	-6.500	0.000	41.200	6	0.000	85.437
Europe	13	0.014	0.006	0.029	-10.726	0.000	56.066	12	0.000	78.597
South-East	10	0.499	0.347	0.651	-0.010	0.992	191.439	9	0.000	95.299
Western	7	0.004	0.002	0.011	-10.994	0.000	9.424	6	0.151	36.330
Total between							306.240	42	0.000	
Overall	48	0.031	0.025	0.039	-29.472	0.000	1111.142	5	0.000	
							1417.382	47	0.000	96.684

Table S26. Prevalence of teicoplanin resistance in blood isolated *E. faecalis*. by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	1	0.006	0.000	0.091	-3.582	0.000	0.000	0	1.000	0.000
Americas	7	0.026	0.012	0.054	-9.310	0.000	30.638	6	0.000	80.417
Eastern	9	0.039	0.024	0.064	-12.180	0.000	20.001	8	0.010	60.001
Europe	17	0.010	0.006	0.017	-17.469	0.000	15.208	16	0.509	0.000
South-East	6	0.041	0.008	0.188	-3.665	0.000	49.023	5	0.000	89.801
Western	1	0.042	0.019	0.090	-7.519	0.000	0.000	0	1.000	0.000
Total between							114.869	35	0.000	
Overall	41	0.023	0.017	0.031	-24.609	0.000	106.409	5	0.000	
							221.278	40	0.000	81.923

Table S27. Prevalence of linezolid resistance in blood isolated *E. faecalis*. by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	**Number Studies**	**Point estimate**	**Lower limit**	**Upper limit**	**Z-value**	**P-value**	**Q-value**	**df (Q)**	**P-value**	**I-squared**
Mixed effects analysis										
Africa	1	0.036	0.005	0.214	-3.236	0.001	0.000	0	1.000	0.000
Americas	8	0.003	0.002	0.006	-17.055	0.000	3.599	7	0.825	0.000
Eastern	6	0.015	0.004	0.058	-5.921	0.000	21.479	5	0.001	76.722
Europe	9	0.004	0.002	0.009	-13.478	0.000	3.312	8	0.913	0.000
South-East	3	0.021	0.002	0.218	-2.938	0.003	11.859	2	0.003	83.135
Western	7	0.005	0.002	0.017	-9.067	0.000	16.520	6	0.011	63.680
Total between							56.769	28	0.001	
Overall	34	0.005	0.003	0.008	-24.484	0.000	76.285	5	0.000	
							133.054	33	0.000	75.198

Table S28. Prevalence of vancomycin resistance in blood isolated *E. faecium* by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	1	0.013	0.001	0.171	-3.070	0.002	0.000	0	1.000	0.000
Americas	10	0.403	0.257	0.568	-1.161	0.246	136.226	9	0.000	93.393
Eastern	11	0.232	0.111	0.423	-2.652	0.008	139.172	10	0.000	92.815
Europe	71	0.065	0.049	0.086	-17.301	0.000	777.279	70	0.000	90.994
South-East	10	0.059	0.021	0.153	-5.122	0.000	47.696	9	0.000	81.130
Western	7	0.205	0.118	0.332	-4.058	0.000	57.311	6	0.000	89.531
Total between							1157.684	104	0.000	
Overall	110	0.107	0.087	0.132	-17.561	0.000	590.090	5	0.000	
							1747.774	109	0.000	93.763

Table S29. Prevalence of gentamicin resistance in blood isolated *E. faecium* by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	1	0.615	0.456	0.753	1.428	0.153	0.000	0	1.000	0.000
Americas	8	0.278	0.152	0.453	-2.444	0.015	81.818	7	0.000	91.444
Eastern	10	0.389	0.200	0.619	-0.942	0.346	145.375	9	0.000	93.809
Europe	17	0.420	0.280	0.574	-1.022	0.307	360.628	16	0.000	95.563
South-East	12	0.497	0.356	0.638	-0.041	0.967	93.007	11	0.000	88.173
Western	7	0.655	0.532	0.760	2.453	0.014	63.091	6	0.000	90.490
Total between							743.919	49	0.000	
Overall	55	0.510	0.444	0.574	0.287	0.774	141.876	5	0.000	
							885.796	54	0.000	93.904

Table S30. Prevalence of ampicillin resistance in blood isolated *E. faecium* by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	1	0.949	0.817	0.987	4.019	0.000	0.000	0	1.000	0.000
Americas	9	0.814	0.764	0.856	9.606	0.000	16.918	8	0.031	52.713
Eastern	7	0.645	0.497	0.770	1.923	0.054	30.334	6	0.000	80.220
Europe	14	0.835	0.782	0.877	9.232	0.000	50.363	13	0.000	74.188
South-East	9	0.506	0.362	0.648	0.075	0.940	48.544	8	0.000	83.520
Western	7	0.862	0.791	0.912	7.097	0.000	25.234	6	0.000	76.223
Total between							171.394	41	0.000	
Overall	47	0.797	0.765	0.825	14.534	0.000	248.662	5	0.000	
							420.057	46	0.000	89.049

Table S31. Prevalence of teicoplanin resistance in blood isolated *E. faecium* by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Africa	1	0.013	0.001	0.171	-3.070	0.002	0.000	0	1.000	0.000
Americas	7	0.292	0.139	0.512	-1.861	0.063	74.018	6	0.000	91.894
Eastern	10	0.197	0.084	0.396	-2.806	0.005	130.545	9	0.000	93.106
Europe	12	0.081	0.041	0.154	-6.579	0.000	85.642	11	0.000	87.156
South-East	7	0.078	0.025	0.222	-3.982	0.000	41.395	6	0.000	85.506
Western	1	0.211	0.109	0.368	-3.322	0.001	0.000	0	1.000	0.000
Total between							331.601	32	0.000	
Overall	38	0.147	0.104	0.203	-8.829	0.000	188.519	5	0.000	
							520.120	37	0.000	92.886

Table S32. Prevalence of linezolid resistance in blood isolated *E. faecium* by WHO original offices.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Americas	8	0.008	0.004	0.020	-10.582	0.000	3.045	7	0.881	0.000
Eastern	7	0.031	0.012	0.077	-6.978	0.000	10.182	6	0.117	41.072
Europe	10	0.013	0.007	0.025	-12.792	0.000	9.442	9	0.397	4.683
South-East	4	0.041	0.018	0.089	-7.444	0.000	3.330	3	0.343	9.918
Western	7	0.014	0.003	0.068	-5.108	0.000	37.709	6	0.000	84.089
Total between							63.708	31	0.000	
Overall	36	0.018	0.012	0.027	-19.918	0.000	17.760	4	0.001	
							81.468	35	0.000	57.038

Table S33. Prevalence of vancomycin resistance in blood isolated *E. faecalis* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
2000-2005	25	0.010	0.005	0.019	-13.835	0.000	100.408	24	0.000	76.097
2005-2010	37	0.022	0.015	0.032	-19.559	0.000	130.387	36	0.000	72.390
2010-2016	24	0.027	0.015	0.049	-11.442	0.000	124.667	23	0.000	81.551
Total between							355.461	83	0.000	
Overall	86	0.020	0.015	0.026	-26.442	0.000	32.198	2	0.000	
							387.659	85	0.000	78.074

Table S34. Prevalence of gentamycin resistance in blood isolated *E. faecalis* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
2000-2005	21	0.365	0.284	0.454	-2.948	0.003	476.206	20	0.000	95.800
2005-2010	23	0.397	0.342	0.454	-3.504	0.000	306.029	22	0.000	92.811
2010-2016	43	0.345	0.301	0.391	-6.253	0.000	872.640	42	0.000	95.187
Total between							1654.875	84	0.000	
Overall	87	0.366	0.334	0.400	-7.620	0.000	84.927	2	0.000	
							1739.802	86	0.000	95.057

Table S35. Prevalence of ampicillin resistance in blood isolated *E. faecalis* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	**Number Studies**	**Point estimate**	**Lower limit**	**Upper limit**	**Z-value**	**P-value**	**Q-value**	**df (Q)**	**P-value**	**I-squared**
Mixed effects analysis										
2000-2005	17	0.040	0.017	0.090	-7.191	0.000	492.540	16	0.000	96.752
2005-2010	14	0.021	0.007	0.060	-6.949	0.000	377.020	13	0.000	96.552
2010-2016	15	0.091	0.037	0.209	-4.639	0.000	245.987	14	0.000	94.309
Total between							1115.547	43	0.000	
Overall	46	0.044	0.026	0.075	-10.822	0.000	290.602	2	0.000	
							1406.149	45	0.000	96.800

Table S36. Prevalence of teicoplanin resistance in blood isolated *E. faecalis* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	**Number Studies**	**Point estimate**	**Lower limit**	**Upper limit**	**Z-value**	**P-value**	**Q-value**	**df (Q)**	**P-value**	**I-squared**
Mixed effects analysis										
2000-2005	9	0.009	0.004	0.020	-10.941	0.000	11.523	8	0.174	30.571
2005-2010	19	0.018	0.009	0.036	-11.497	0.000	142.323	18	0.000	87.353
2010-2016	13	0.044	0.024	0.079	-9.717	0.000	45.139	12	0.000	73.415
Total between							198.984	38	0.000	
Overall	41	0.023	0.015	0.033	-18.332	0.000	42.981	2	0.000	
							241.965	40	0.000	83.469

Table S37. Prevalence of linezolid resistance in blood isolated *E. faecalis* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
2000-2005	6	0.003	0.001	0.008	-10.968	0.000	1.602	5	0.901	0.000
2005-2010	15	0.004	0.001	0.010	-10.755	0.000	54.833	14	0.000	74.468
2010-2016	13	0.021	0.008	0.054	-7.894	0.000	71.107	12	0.000	83.124
Total between							127.542	31	0.000	
Overall	34	0.007	0.004	0.012	-16.980	0.000	46.242	2	0.000	
							173.784	33	0.000	81.011

Table S38. Prevalence of vancomycin resistance in blood isolated *E. faecium* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
2000-2005	24	0.082	0.052	0.126	-9.794	0.000	119.681	23	0.000	80.782
2005-2010	62	0.089	0.064	0.123	-12.667	0.000	1255.061	61	0.000	95.140
2010-2016	21	0.218	0.137	0.327	-4.490	0.000	184.315	20	0.000	89.149
Total between							1559.057	104	0.000	
Overall	107	0.106	0.084	0.133	-16.283	0.000	164.754	2	0.000	
							1723.812	106	0.000	93.851

Table S39. Prevalence of gentamycin resistance in blood isolated *E. faecium* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
2000-2005	20	0.424	0.279	0.584	-0.929	0.353	378.867	19	0.000	94.985
2005-2010	20	0.437	0.339	0.541	-1.187	0.235	261.908	19	0.000	92.746
2010-2016	12	0.575	0.421	0.716	0.958	0.338	170.244	11	0.000	93.539
Total between							811.019	49	0.000	
Overall	52	0.467	0.393	0.543	-0.839	0.401	41.509	2	0.000	
							852.528	51	0.000	94.018

Table S40. Prevalence of ampicillin resistance in blood isolated *E. faecium* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	**Number Studies**	**Point estimate**	**Lower limit**	**Upper limit**	**Z-value**	**P-value**	**Q-value**	**df (Q)**	**P-value**	**I-squared**
Mixed effects analysis										
2000-2005	16	0.746	0.649	0.823	4.580	0.000	124.163	15	0.000	87.919
2005-2010	17	0.808	0.751	0.854	8.460	0.000	94.906	16	0.000	83.141
2010-2016	11	0.766	0.618	0.869	3.295	0.001	108.934	10	0.000	90.820
Total between							328.004	41	0.000	
Overall	44	0.785	0.740	0.825	10.088	0.000	40.559	2	0.000	
							368.563	43	0.000	88.333

Table S41. Prevalence of teicoplanin resistance in blood isolated *E. faecium* by study time groups.

Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
2000-2005	9	0.112	0.068	0.177	-7.547	0.000	18.825	8	0.016	57.504
2005-2010	15	0.131	0.063	0.254	-4.562	0.000	251.261	14	0.000	94.428
2010-2016	11	0.243	0.119	0.433	-2.572	0.010	138.770	10	0.000	92.794
Total between							408.856	32	0.000	
Overall	35	0.138	0.097	0.193	-9.007	0.000	82.074	2	0.000	
							490.930	34	0.000	93.074

Table S42. Prevalence of vancomycin resistance in blood isolated *E. faecalis* by country.

Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Mixed effects analysis										
Algeria	1	0.006	0.000	0.091	-3.582	0.000	0.000	0	1.000	0.000
Argentina	1	0.008	0.002	0.032	-6.754	0.000	0.000	0	1.000	0.000
Australia	1	0.005	0.001	0.014	-9.308	0.000	0.000	0	1.000	0.000
Brazil	2	0.077	0.064	0.091	-25.307	0.000	0.000	1	0.986	0.000
Chile	1	0.011	0.004	0.033	-7.770	0.000	0.000	0	1.000	0.000
Colombia	1	0.050	0.021	0.113	-6.442	0.000	0.000	0	1.000	0.000
Cuba	1	0.012	0.002	0.080	-4.392	0.000	0.000	0	1.000	0.000
Denmark	2	0.008	0.002	0.037	-5.930	0.000	0.161	1	0.688	0.000
Egypt	1	0.071	0.030	0.160	-5.527	0.000	0.000	0	1.000	0.000
France	3	0.012	0.002	0.058	-5.336	0.000	3.206	2	0.201	37.613
Germany	1	0.004	0.000	0.064	-3.852	0.000	0.000	0	1.000	0.000
Greece	15	0.008	0.004	0.013	-17.485	0.000	5.828	14	0.971	0.000
India	10	0.032	0.016	0.061	-9.884	0.000	17.916	9	0.036	49.764
Iran	8	0.060	0.029	0.119	-7.152	0.000	36.315	7	0.000	80.724
Ireland	1	0.013	0.001	0.175	-3.052	0.002	0.000	0	1.000	0.000
Israel	2	0.009	0.001	0.059	-4.712	0.000	0.246	1	0.620	0.000
Italy	2	0.012	0.007	0.022	-15.099	0.000	0.091	1	0.763	0.000
Japan	1	0.181	0.126	0.252	-6.982	0.000	0.000	0	1.000	0.000
Kenya	1	0.017	0.001	0.223	-2.834	0.005	0.000	0	1.000	0.000
Mexico	1	0.002	0.000	0.024	-4.577	0.000	0.000	0	1.000	0.000
Nepal	1	0.110	0.056	0.204	-5.591	0.000	0.000	0	1.000	0.000
Netherlands	1	0.008	0.001	0.120	-3.365	0.001	0.000	0	1.000	0.000
Norway	1	0.016	0.001	0.211	-2.883	0.004	0.000	0	1.000	0.000
Poland	8	0.009	0.003	0.022	-9.993	0.000	0.743	7	0.998	0.000
Saudi Arabia	1	0.018	0.006	0.055	-6.857	0.000	0.000	0	1.000	0.000
Spain	4	0.008	0.002	0.027	-7.584	0.000	2.338	3	0.505	0.000
Sweden	2	0.002	0.000	0.017	-6.001	0.000	0.556	1	0.456	0.000
Switzerland	1	0.023	0.001	0.277	-2.629	0.009	0.000	0	1.000	0.000
Taiwan	5	0.004	0.002	0.008	-13.161	0.000	1.175	4	0.882	0.000
Tunis	1	0.004	0.000	0.054	-3.975	0.000	0.000	0	1.000	0.000
Turkey	3	0.005	0.001	0.026	-6.386	0.000	0.478	2	0.787	0.000
UK	2	0.075	0.012	0.354	-2.578	0.010	8.420	1	0.004	88.124
USA	2	0.074	0.030	0.173	-5.134	0.000	10.814	1	0.001	90.753

Table S43. Prevalence of vancomycin resistance in blood isolated *E. faecium* by country.

Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Algeria	1	0.013	0.001	0.171	-3.070	0.002	0.000	0	1.000	0.000
Argentina	1	0.365	0.247	0.503	-1.917	0.055	0.000	0	1.000	0.000
Australia	1	0.365	0.318	0.415	-5.150	0.000	0.000	0	1.000	0.000
Austria	1	0.032	0.018	0.055	-11.630	0.000	0.000	0	1.000	0.000
Belgium	1	0.014	0.005	0.043	-7.298	0.000	0.000	0	1.000	0.000
Brazil	2	0.673	0.612	0.729	5.336	0.000	0.215	1	0.643	0.000
Bulgaria	1	0.012	0.001	0.160	-3.123	0.002	0.000	0	1.000	0.000
Canada	1	0.171	0.119	0.239	-7.327	0.000	0.000	0	1.000	0.000
Chile	1	0.407	0.285	0.542	-1.353	0.176	0.000	0	1.000	0.000
Colombia	1	0.389	0.198	0.621	-0.935	0.350	0.000	0	1.000	0.000
Croatia	1	0.008	0.001	0.116	-3.389	0.001	0.000	0	1.000	0.000
Cuba	1	0.100	0.014	0.467	-2.084	0.037	0.000	0	1.000	0.000
Cyprus	1	0.103	0.034	0.276	-3.542	0.000	0.000	0	1.000	0.000
Czech	1	0.115	0.081	0.159	-10.543	0.000	0.000	0	1.000	0.000
Denmark	2	0.019	0.011	0.033	-14.053	0.000	0.480	1	0.488	0.000
Egypt	2	0.133	0.032	0.419	-2.373	0.018	4.005	1	0.045	75.034
Estonia	1	0.012	0.001	0.167	-3.088	0.002	0.000	0	1.000	0.000
Finland	1	0.007	0.002	0.029	-6.922	0.000	0.000	0	1.000	0.000
France	4	0.010	0.004	0.021	-11.741	0.000	0.920	3	0.821	0.000
Germany	2	0.163	0.137	0.191	-16.231	0.000	0.002	1	0.963	0.000
Greece	16	0.105	0.081	0.136	-14.420	0.000	22.564	15	0.094	33.522
Hungary	1	0.035	0.015	0.082	-7.271	0.000	0.000	0	1.000	0.000
Iceland	1	0.033	0.002	0.366	-2.341	0.019	0.000	0	1.000	0.000
India	8	0.081	0.029	0.209	-4.350	0.000	36.045	7	0.000	80.580
Iran	6	0.436	0.208	0.696	-0.463	0.643	92.973	5	0.000	94.622
Ireland	2	0.548	0.288	0.784	0.343	0.732	3.705	1	0.054	73.012
Israel	2	0.134	0.006	0.807	-1.109	0.268	4.700	1	0.030	78.725
Italy	3	0.133	0.053	0.297	-3.632	0.000	32.550	2	0.000	93.856
Japan	1	0.579	0.419	0.724	0.969	0.332	0.000	0	1.000	0.000
Latvia	1	0.056	0.008	0.307	-2.753	0.006	0.000	0	1.000	0.000
Lithuania	1	0.056	0.014	0.197	-3.894	0.000	0.000	0	1.000	0.000
Luxembourg	1	0.024	0.001	0.287	-2.594	0.009	0.000	0	1.000	0.000
Mexico	1	0.004	0.000	0.058	-3.927	0.000	0.000	0	1.000	0.000
Nepal	1	0.040	0.006	0.235	-3.114	0.002	0.000	0	1.000	0.000
Netherlands	1	0.001	0.000	0.016	-4.860	0.000	0.000	0	1.000	0.000
Norway	1	0.006	0.001	0.041	-5.103	0.000	0.000	0	1.000	0.000
Poland	9	0.055	0.022	0.128	-6.004	0.000	53.468	8	0.000	85.038
Portugal	1	0.233	0.186	0.289	-8.063	0.000	0.000	0	1.000	0.000
Saudi Arabia	1	0.185	0.079	0.375	-2.991	0.003	0.000	0	1.000	0.000
Slovakia	1	0.049	0.018	0.123	-5.794	0.000	0.000	0	1.000	0.000
Slovenia	1	0.005	0.000	0.078	-3.704	0.000	0.000	0	1.000	0.000
Spain	3	0.052	0.009	0.242	-3.237	0.001	9.879	2	0.007	79.756
Sweden	4	0.025	0.008	0.070	-6.603	0.000	9.707	3	0.021	69.096
Switzerland	1	0.100	0.006	0.674	-1.474	0.140	0.000	0	1.000	0.000
Taiwan	6	0.067	0.026	0.158	-5.360	0.000	39.053	5	0.000	87.197
Tunis	2	0.007	0.001	0.045	-5.008	0.000	0.365	1	0.546	0.000
Turkey	6	0.033	0.005	0.196	-3.369	0.001	57.381	5	0.000	91.286
UK	4	0.113	0.059	0.205	-5.718	0.000	13.650	3	0.003	78.023
USA	4	0.266	0.040	0.757	-0.926	0.355	337.058	3	0.000	99.110

References:

1. Hsueh P-R, Liu Y-C, Yang D, Yan J-J, Wu T-L, Huang W-K, et al. Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microbial Drug Resistance. 2001;7(4):373-82.
2. Wroblewska M, Marchel H, Luczak M. Multidrug resistance in bacterial isolates from blood cultures of haematology patients. International journal of antimicrobial agents. 2002;19(3):237-40.
3. Rodríguez JL, Vázquez GJ, Bermúdez M, De Orbeta J, García Y, Rivera Y, et al. Prospective study using standardized methodology for antimicrobial susceptibility of Gram-positive cocci isolated from the Puerto Rico Medical Center. Puerto Rico health sciences journal. 2002;21(4).
4. Perez-Hernandez X, Mendez-Alvarez S, Delgado T, Moreno A, Reyes-Darias J, Lopez AS, et al. Low prevalence of vancomycin-resistant enterococci in clinical samples from hospitalized patients of the Canary Islands, Spain. International Microbiology. 2002;5(3):117-20.
5. Woodford N, Reynolds R, Turton J, Scott F, Sinclair A, Williams A, et al. Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland. Journal of Antimicrobial Chemotherapy. 2003;52(4):711-4.
6. Arias C, Reyes J, Zuniga M, Cortés L, Cruz C, Rico C, et al. Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001–2002. Journal of Antimicrobial Chemotherapy. 2003;51(1):59-68.
7. Johnson A, Henwood C, Mushtaq S, James D, Warner M, Livermore D, et al. Susceptibility of Gram-positive bacteria from ICU patients in UK hospitals to antimicrobial agents. Journal of Hospital Infection. 2003;54(3):179-87.
8. Mathur P, Kapil A, Chandra R, Sharma P, Das B. Antimicrobial resistance in Enterococcus faecalis at a tertiary care centre of northern India. Indian Journal of Medical Research. 2003;118:25-8.
9. Feizabadi MM, Aliahmadi A, Mobasheri F, Asgharzadeh A, Asadi S, Etemadi G. Phenotypic characteristics and population genetics of Enterococcus faecalis cultured from patients in Tehran during 2000–2001. Canadian journal of microbiology. 2003;49(10):645-9.
10. Karmarkar M, Gershom ES, Mehta P. Enterococcal infections with special reference to phenotypic characterization & drug resistance. Indian Journal of Medical Research. 2004;119:22-5.
11. Blahova J, Kralikova K, Krćméry V, Babalova M, Menkyna R, Glosova L, et al. Monitoring of antibiotic resistance in bacterial isolates from bacteremic patients. Journal of chemotherapy. 2004;16(3):269-72.
12. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). International journal of antimicrobial agents. 2004;24(2):111-8.
13. Kapoor L, Randhawa V, Deb M. Antimicrobial resistance of enterococcal blood isolates at a pediatric care hospital in India. Jpn J Infect Dis. 2005;58(2):101-3.
14. Stampone L, Del Grosso M, Boccia D, Pantosti A. Clonal spread of a vancomycin-resistant Enterococcus faecium strain among bloodstream-infecting isolates in Italy. Journal of clinical microbiology. 2005;43(4):1575-80.
15. Quiñones D, Goñi P, Rubio MC, Duran E, Gómez-Lus R. Enterococci spp. isolated from Cuba: species frequency of occurrence and antimicrobial susceptibility profile. Diagnostic microbiology and infectious disease. 2005;51(1):63-7.
16. Kaçmaz B, Aksoy A. Antimicrobial resistance of enterococci in Turkey. International journal of antimicrobial agents. 2005;25(6):535-8.
17. Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC infectious diseases. 2007;7(1):29.
18. Shaked H, Carmeli Y, Schwartz D, Siegman-Igra Y. Enterococcal bacteraemia: epidemiological, microbiological, clinical and prognostic characteristics, and the impact of high level gentamicin resistance. Scandinavian journal of infectious diseases. 2006;38(11-12):995-1000.
19. Klibi N, Gharbi S, Masmoudi A, Ben Slama K, Poeta P, Zarazaga M, et al. Antibiotic resistance and mechanisms implicated in clinical enterococci in a Tunisian hospital. Journal of chemotherapy. 2006;18(1):20-6.
20. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrobial agents and chemotherapy. 2006;50(10):3479-84.

21. Ghoshal U, Garg A, Tiwari DP, Ayyagari A. Emerging vancomycin resistance in enterococci in India. 2006.
22. Młynarczyk G, Grzybowska W, Młynarczyk A, Tyski S, Kawecki D, Łuczak M, et al., editors. Significant increase in the isolation of glycopeptide-resistant enterococci from patients hospitalized in the transplant surgery ward in 2004–2005. Transplantation proceedings; 2007: Elsevier.
23. Mendiratta D, Kaur H, Deotale V, Thamke D, Narang R, Narang P. Status of high level aminoglycoside resistant Enterococcus faecium and Enterococcus faecalis in a rural hospital of central India. Indian journal of medical microbiology. 2008;26(4):369.
24. Emaneini M, Aligholi M, Aminshahi M. Characterization of glycopeptides, aminoglycosides and macrolide resistance among Enterococcus faecalis and Enterococcus faecium isolates from hospitals in Tehran. Pol J Microbiol. 2008;57(2):173-8.
25. Agarwal J, Kalyan R, Singh M. High-level aminoglycoside resistance and Beta-lactamase production in enterococci at a tertiary care hospital in India. Jpn J Infect Dis. 2009;62(2):158-9.
26. Billström H, Lund B, Sullivan Å, Nord CE. Virulence and antimicrobial resistance in clinical Enterococcus faecium. International journal of antimicrobial agents. 2008;32(5):374-7.
27. Zhanel GG, Adam HJ, Low DE, Blondeau J, DeCorby M, Karlowsky JA, et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007–2009 study. Diagnostic microbiology and infectious disease. 2011;69(3):291-306.
28. Al-Jarousha A-MK, Saed A, Afifi H. Prevalence of multidrug resistant enterococci in nosocomial infection in Gaza strip. J Al-Aqsa Unv. 2008;12:15-24.
29. Claesson C, Nilsson LE, Kronvall G, Walder M, Sörberg M. Antimicrobial activity of tigecycline and comparative agents against clinical isolates of staphylococci and enterococci from ICUs and general hospital wards at three Swedish university hospitals. Scandinavian journal of infectious diseases. 2009;41(3):171-81.
30. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. Journal of Antimicrobial chemotherapy. 2009;63(4):785-94.
31. Gales AC, Sader HS, Ribeiro J, Zoccoli C, Barth A, Pignatari AC. Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008). Brazilian Journal of Infectious Diseases. 2009;13(2):90-8.
32. Yasliani S, Mohabati Mobarez A, Doust RH, Satari M, Teymornejad O. Linezolid vancomycin resistant Enterococcus isolated from clinical samples in Tehran hospitals. Indian journal of medical sciences. 2009;63(7).
33. Adhikari L. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial enterococci. Journal of global infectious diseases. 2010;2(3):231.
34. Protonotariou E, Dimitroulia E, Pournaras S, Pitiriga V, Sofianou D, Tsakris A. Trends in antimicrobial resistance of clinical isolates of Enterococcus faecalis and Enterococcus faecium in Greece between 2002 and 2007. Journal of Hospital Infection. 2010;75(3):225-7.
35. Kohli R, Omuse G, Revathi G. Antibacterial susceptibility patterns of blood stream isolates in patients investigated at the Aga Khan University Hospital, Nairobi. East African medical journal. 2010;87(2):75-81.
36. Araoka H, Kimura M, Yoneyama A. A surveillance of high-level gentamicin-resistant enterococcal bacteremia. Journal of Infection and Chemotherapy. 2011;17(3):433-4.
37. Jain S, Kumar A, Kashyap B, Kaur IR. Clinico-epidemiological profile and high-level aminoglycoside resistance in enterococcal septicemia from a tertiary care hospital in east Delhi. International Journal of Applied and Basic Medical Research. 2011;1(2):80.
38. Zhanel GG, DeCorby M, Laing N, Weshnoweski B, Vashisht R, Tailor F, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrobial agents and chemotherapy. 2008;52(4):1430-7.
39. Mira M-U, Deana M, Zora J, Vera G, Biljana M, Biljana R. Prevalence of different enterococcal species isolated from blood and their susceptibility to antimicrobial drugs in Vojvodina, Serbia, 2011-2013. African journal of microbiology research. 2014;8(8):819-24.
40. Aslan S, Citak EC, Yis R, Degirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian journal of microbiology. 2012;52(2):203-8.
41. Olawale KO, Fadiora SO, Taiwo SS. Prevalence of hospital acquired enterococci infections in two primary-care hospitals in Osogbo, Southwestern Nigeria. African journal of infectious diseases. 2011;5(2).
42. Conceição N, Oliveira CdCHB, Silva PRd, Ávila BGM, Oliveira AGd. Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study. Revista da Sociedade Brasileira de Medicina Tropical. 2011;44(2):177-81.
43. Prevention ECfD, Control. Antimicrobial resistance surveillance in Europe 2013. ECDC Stockholm; 2014.

44. Hammerum AM, Lester CH, Olsen SS, Holm A, Hansen DS, Schønheyder HC. Molecular characterisation of high-level gentamicin-resistant enterococci from bloodstream infections in Denmark: first description of clonal spread of aph (2'')-Ib. International journal of antimicrobial agents. 2012;39(3):266-8.
45. El-Din RAA, El-Mahdy HS. Molecular characterization of enterococcus strains isolated from cases of neonatal sepsis in neonatal intensive care unit. African Journal of Microbiology Research. 2013;6(44):7206-11.
46. Kuch A, Willems RJ, Werner G, Coque TM, Hammerum AM, Sundsfjord A, et al. Insight into antimicrobial susceptibility and population structure of contemporary human Enterococcus faecalis isolates from Europe. Journal of antimicrobial chemotherapy. 2011;67(3):551-8.
47. Salem-Bekhit M, Moussa I, Muharram M, Alanazy F, Hefni H. Prevalence and antimicrobial resistance pattern of multidrug-resistant enterococci isolated from clinical specimens. Indian journal of medical microbiology. 2012;30(1):44.
48. Nepal H, Khanal B, Acharya A, Gyawali N, Jha P, Paudel R. High-level gentamicin resistance and vancomycin resistance in clinical isolates of enterococci in a tertiary care hospital in eastern Nepal. Nepal Medical College journal: NMCJ. 2012;14(1):60-3.
49. Djahmi N, Boutet-Dubois A, Nedjai S, Dekhil M, Sotto A, Lavigne J-P. Molecular epidemiology of Enterococcus sp. isolated in a university hospital in Algeria. Scandinavian journal of infectious diseases. 2012;44(9):656-62.
50. Sreeja S, Sreenivasa Babu P, Prathab A. The prevalence and the characterization of the enterococcus species from various clinical samples in a tertiary care hospital. Journal of clinical and diagnostic research: JCDR. 2012;6(9):1486.
51. Soltani R, Khalili H, Abdollahi A, Rasoolinejad M, Dashti-Khavidaki S. Nosocomial Gram-positive antimicrobial susceptibility pattern at a referral teaching hospital in Tehran, Iran. Future microbiology. 2012;7(7):903-10.
52. Khalili H, Dashti-Khavidaki S, Karimzadeh I, Jafari S, Abdollahi A, Shahidi MR, et al. Changes in 4-year antimicrobial resistance pattern of gram-positive bacteria at the main referral teaching hospital, Tehran, Iran. Acta Medica Iranica. 2012;50(7):493-504.
53. Sharifi Y, Hasani A, Ghotaslou R, Varshochi M, Hasani A, Soroush MH, et al. Vancomycin-resistant enterococci among clinical isolates from north-west Iran: identification of therapeutic surrogates. Journal of medical microbiology. 2012;61(4):600-2.
54. Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T, et al. Molecular epidemiology of enterococcal bacteremia in Australia. Journal of clinical microbiology. 2014;52(3):897-905.
55. Wang J-T, Chang S-C, Wang H-Y, Chen P-C, Shiau Y-R, Lauderdale T-L. High rates of multidrug resistance in Enterococcus faecalis and E. faecium isolated from inpatients and outpatients in Taiwan. Diagnostic microbiology and infectious disease. 2013;75(4):406-11.
56. Fernandes SC, Dhanashree B. Drug resistance & virulence determinants in clinical isolatesof Enterococcus species. The Indian journal of medical research. 2013;137(5):981.
57. Praharaj I, Sujatha S, Parija SC. Phenotypic & genotypic characterization of vancomycin resistant Enterococcus isolates from clinical specimens. The Indian journal of medical research. 2013;138(4):549.
58. Celik S, Cakirlar FK, Torun MM. Presence of vancomycin, aminoglycosides and erythromycin resistance genes in enterococci isolated from clinical samples in Turkey. Clinical laboratory. 2014;60(11):1801-6.
59. KAFIL HS, ASGHARZADEH M. Vancomycin-resistant enteroccus faecium and enterococcus faecalis isolated from education hospital of iran. Maedica. 2014;9(4):323.
60. Padmasini E, Padmaraj R, Ramesh SS. High level aminoglycoside resistance and distribution of aminoglycoside resistant genes among clinical isolates of Enterococcus species in Chennai, India. The Scientific World Journal. 2014;2014.
61. Moemen D, Tawfeek D, Badawy W. Healthcare-associated vancomycin resistant Enterococcus faecium infections in the Mansoura University Hospitals intensive care units, Egypt. Brazilian Journal of Microbiology. 2015;46(3):777-83.
62. Sirkhazi M, Sarriff A, Aziz NA, Almana F, Arafat O, Shorman M. Bacterial Spectrum, Isolation Sites and Susceptibility Patterns of Pathogens in Adult Febrile Neutropenic Cancer Patients at a Specialist Hospital in Saudi Arabia. World journal of oncology. 2014;5(5-6):196.
63. Babar N, Usman J, Munir T, Gill MM, Anjum R, Gilani M, et al. Frequency and antibiogram of vancomycin resistant enterococcus in a tertiary care hospital. J Coll Physicians Surg Pak. 2014;24(1):27-9.
64. Abat C, Raoult D, Rolain J-M. Low level of resistance in enterococci isolated in four hospitals, Marseille, France. Microbial Drug Resistance. 2016;22(3):218-22.
65. Kajihara T, Nakamura S, Iwanaga N, Oshima K, Takazono T, Miyazaki T, et al. Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: a retrospective study. BMC infectious diseases. 2015;15(1):426.

66. Bhatt P, Maj AP, Brig AS, Retd APSC, Col NG, Das NK, et al. Emergence of multidrug resistant enterococci at a tertiary care centre. medical journal armed forces india. 2015;71(2):139-44.
67. Nasaj M, Mousavi SM, Hosseini SM, Arabestani MR. Prevalence of virulence factors and vancomycin-resistant genes among Enterococcus faecalis and E. faecium isolated from clinical specimens. Iranian journal of public health. 2016;45(6):806.
68. Chakraborty A, Pal NK, Sarkar S, Gupta MS. Antibiotic resistance pattern of Enterococci isolates from nosocomial infections in a tertiary care hospital in Eastern India. Journal of natural science, biology, and medicine. 2015;6(2):394.
69. Zadeh AH, Shojapour M, Nazari R, Akbari M, Sofian M, Abtahi H. Genotyping of vancomycin resistant enterococci in arak hospitals. Jundishapur journal of microbiology. 2015;8(4).
70. Maina D, Omuse G, Revathi G, Adam RD. Spectrum of microbial diseases and resistance patterns at a private teaching hospital in Kenya: implications for clinical practice. PloS one. 2016;11(1):e0147659.
71. Gawryszewska I, Żabicka D, Bojarska K, Malinowska K, Hryniewicz W, Sadowy E. Invasive enterococcal infections in Poland: the current epidemiological situation. European Journal of Clinical Microbiology & Infectious Diseases. 2016;35(5):847-56.
72. Arabestani MR, Nasaj M, Mousavi SM. Correlation between infective factors and antibiotic resistance in Enterococci clinical isolates in West of Iran. Chonnam medical journal. 2017;53(1):56-63.
73. Tuhina B, Anupurba S, Karuna T. Emergence of antimicrobial resistance and virulence factors among the unusual species of enterococci, from North India. Indian Journal of Pathology and Microbiology. 2016;59(1):50.
74. Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE, Jones RN. Linezolid surveillance results for the United States (LEADER surveillance program 2014). Antimicrobial agents and chemotherapy. 2016:AAC. 02803-15.
75. Biswas PP, Dey S, Sen A, Adhikari L. Molecular characterization of virulence genes in vancomycin-resistant and vancomycin-sensitive enterococci. Journal of global infectious diseases. 2016;8(1):16.
76. Mittal S, Singla P, Deep A, Bala K, Sikka R, Garg M, et al. Vancomycin and high level aminoglycoside resistance in Enterococcus spp. in a tertiary health care centre: a therapeutic concern. Journal of pathogens. 2016;2016.
77. Phukan C, Lahkar M, Ranotkar S, Saikia KK. Emergence of vanA gene among vancomycin-resistant enterococci in a tertiary care hospital of North-East India. The Indian journal of medical research. 2016;143(3):357.
78. Armin S, Fallah F, Karimi A, Rashidan M, Shirdust M, Azimi L. Genotyping, antimicrobial resistance and virulence factor gene profiles of vancomycin resistance Enterococcus faecalis isolated from blood culture. Microbial pathogenesis. 2017;109:300-4.
79. Jaramago JM, Ibáñez RA, Miñana JC, Suárez-Varela MM. Perfiles de resistencia y factores de riesgo de microorganismos resistentes en bacteriemia de origen abdominal. Revista Española de Anestesiología y Reanimación. 2017;64(9):490-8.
80. Jahansepas A, Aghazadeh M, Rezaee MA, Hasani A, Sharifi Y, Aghazadeh T, et al. Occurrence of Enterococcus faecalis and Enterococcus faecium in Various Clinical Infections: Detection of Their Drug Resistance and Virulence Determinants. Microbial Drug Resistance. 2018;24(1):76-82.
81. Yilema A, Moges F, Tadele S, Endris M, Kassu A, Abebe W, et al. Isolation of enterococci, their antimicrobial susceptibility patterns and associated factors among patients attending at the University of Gondar Teaching Hospital. BMC infectious diseases. 2017;17(1):276.
82. Pitiriga V, Kanellopoulos P, Kampos E, Panagiotakopoulos G, Tsakris A, Saroglou G. Antimicrobial stewardship program in a Greek hospital: implementing a mandatory prescription form and prospective audits. Future microbiology. 2018(0).
83. Karimzadeh I, Mirzaee M, Sadeghimanesh N, Sagheb MM. Antimicrobial resistance pattern of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz, Southwest Iran. Journal of research in pharmacy practice. 2016;5(4):238.